Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fixed Rate Continuous Subcutaneous Glucagon Infusion (CSGI) vs Placebo in Type 1 Diabetes Mellitus Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses to Insulin-Induced Hypoglycemia

NCT03490942 is registered in ClinicalTrials.gov with Xeris Pharmaceuticals as lead sponsor.

NCT NCT03490942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03490942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fixed Rate Continuous Subcutaneous Glucagon Infusion (CSGI) vs Placebo in Type 1 Diabetes Mellitus Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses to Insulin-Induced Hypoglycemia
Lead sponsor
Xeris Pharmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
March 15, 2018
Completion date
February 10, 2020
Enrollment
49 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 1, hypoglycemia unawareness